Every Form 4 that NeoGenomics, Inc. (NEO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEO filings page.
NeoGenomics, Inc. (NEO) executive Alicia C. Olivo reported one routine tax-related share disposition and updated her equity award holdings. On September 1, 2026, 2,692 shares of common stock were surrendered to NeoGenomics for retirement to satisfy tax obligations upon the vesting of restricted stock, leaving her with 90,875 common shares held directly. The filing also details her outstanding stock options, restricted stock units, and performance stock units across multiple grant dates, with exercise prices ranging from $9.45 to $48.99 and expirations extending to 2036, and no Rule 10b5-1 trading plan is reported.
NEOGENOMICS INC (NEO) reported that officer Warren Stone, President & Chief Operating Officer, exercised 28,106 Restricted Stock Units into an equal number of shares of common stock on August 21, 2026. On the same date, 11,060 shares of common stock were delivered or withheld for payment of exercise price or tax liability. The filing also lists Mr. Stone’s remaining equity incentives, including multiple tranches of stock options, restricted stock units, and performance stock units that vest over future dates and, once vested, common shares that are not subject to expiration.
NeoGenomics Inc. chief accounting officer Greg D. Aunan reported selling 20,000 shares of Common Stock on 2026-08-04 at $16.07 per share, leaving 5,153 shares held directly. He continues to hold multiple equity awards, including restricted stock units for 10,745 underlying shares and stock options for 28,662, 26,978, 31,163 and 36,825 underlying shares with exercise prices between $9.83 and $14.62.
NEOGENOMICS INC director Carolyn S. Starrett reported receiving new equity awards. On 2026-06-23, she was granted 14,125 Restricted Stock Units, each representing one share of common stock when vested. She was also granted stock options for 9,784 shares of common stock at an exercise price of $11.20 per share, expiring on 2036-06-01. A footnote states that once vested, the common shares underlying these awards are not subject to expiration.
NeoGenomics director Lynn A. Tetrault reported an open-market sale of 5,307 shares of Common Stock at $11.10 per share on June 15, 2026. After this transaction, she directly holds 86,115 Common shares.
She also indirectly holds 7,000 Common shares through a Lynn Tetrault Rollover IRA. In addition, she has 15,970 Restricted Stock Units tied to Common Stock and multiple stock option grants covering various numbers of underlying shares with exercise prices ranging from $8.10 to $41.76 and expirations between 2026 and 2036.
NEOGENOMICS INC director Lynn A. Tetrault sold 5,307 shares of common stock at $11.29 per share in an open-market transaction on June 9, 2026. After this sale, she directly held 91,422 common shares and indirectly held 7,000 shares through a Lynn Tetrault Rollover IRA.
She also reported equity awards that can convert into common stock, including 15,970 restricted stock units and multiple stock option grants covering tens of thousands of shares at exercise prices ranging from $8.10 to $41.76 per share with expirations between 2026 and 2036.
NeoGenomics Inc. director John P. Kenny reported equity compensation and an option exercise involving company stock. He exercised restricted stock units into 5,893 shares of common stock at $0.00 per share and now holds 5,893 common shares directly.
He also received a grant of 15,970 restricted stock units and 11,069 stock options exercisable at $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. A separate stock option covering 4,171 shares at an exercise price of $11.76 remains outstanding and is scheduled to expire on January 1, 2036.
NeoGenomics, Inc. director Felicia Williams reported multiple equity compensation events. She exercised previously granted restricted stock units, receiving 23,077 shares of common stock at a price of $0.00 per share, and now directly owns 30,237 common shares following the transactions.
She was also granted 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, both relating to NeoGenomics common stock. In addition, she continues to hold options covering 16,107 shares at an exercise price of $7.28 per share expiring June 1, 2035, and 5,430 shares at $13.59 per share expiring June 1, 2034.
NeoGenomics director Lynn A. Tetrault reported equity award activity and updated holdings. On 2026-06-01, she acquired 23,077 shares of Common Stock through the exercise of previously reported restricted stock units at $0.00 per share, bringing her direct Common Stock holdings to 96,729 shares.
She also received new equity compensation in the form of 15,970 Restricted Stock Units and 11,069 Stock Options with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on 2027-06-01. In addition, she holds 7,000 shares of Common Stock indirectly through the Lynn Tetrault Rollover IRA and maintains several previously granted option positions with exercise prices ranging from $7.28 to $41.76 and expirations through 2035.
NeoGenomics Inc. director David Brian Perez reported multiple equity compensation movements. On June 1, 2026, he exercised restricted stock units into 23,077 shares of common stock, bringing his direct common stock holdings to 56,967 shares. He also received a new grant of 15,970 restricted stock units, each convertible into one share of common stock, and a new stock option for 11,069 shares with a strike price of $10.52 per share expiring in 2036. Perez continues to hold 10,000 common shares indirectly through the Perez Joint Revocable Trust. The filing shows no open‑market buys or sells, only option and RSU grants and exercises related to compensation.
NeoGenomics director Michael Aaron Kelly reported equity compensation activity. On June 1, 2026, he exercised 23,077 restricted stock units into common stock at $0.00 per share, bringing his direct common stock holdings to 67,086 shares. A trust associated with him also holds 5,000 common shares indirectly.
He received a new grant of 15,970 restricted stock units and 11,069 stock options with a $10.52 exercise price, both scheduled to vest or become exercisable on June 1, 2027. The filing also lists several existing stock option awards with exercise prices ranging from $7.28 to $40.90 and expirations between 2027 and 2035, indicating a continuing long-term equity position.
NEOGENOMICS INC director Stephen M. Kanovsky reported equity compensation activity involving company stock. He exercised previously granted restricted stock units into 23,077 shares of Common Stock at $0.00 per share, bringing his direct Common Stock holdings to 75,421 shares. The filing notes this reflects the release of restricted stock units that were previously reported, and that once vested, the resulting shares are not subject to expiration.
Kanovsky also received new equity awards: 15,970 restricted stock units tied to Common Stock and a stock option for 11,069 shares of Common Stock with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. He continues to hold multiple existing stock option grants with exercise prices ranging from $7.28 to $40.90 per share and expiration dates from 2026 through 2035, providing additional potential future share exposure.
NeoGenomics Inc. director Neil Gunn reported compensation-related equity activity. On 2026-06-01, 23,077 restricted stock units vested and were exercised into an equal number of common shares at $0.00 per share, bringing his direct common stock holdings to 51,177.31 shares.
Gunn also received new awards of 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, exercisable from 2027-06-01 and expiring on 2036-06-01. Existing stock options with exercise prices ranging from $7.28 to $14.82 and expirations from 2033-08-10 to 2035-06-01 remain outstanding.
NEOGENOMICS INC director Marjorie C. Green reported equity compensation activity and an option-related share issuance. She exercised previously reported restricted stock units into 22,964 shares of common stock, which she now holds directly. She also received new awards of 15,970 restricted stock units scheduled to vest on June 1, 2027 and 11,069 stock options exercisable at $10.52 per share expiring on June 1, 2036. A separate option position covering 16,019 underlying shares at an exercise price of $6.95 per share remains outstanding and expires on June 19, 2035. The filing shows only grants and exercises, with no open‑market purchases or sales.
NeoGenomics, Inc. executive Alicia C. Olivo, EVP, GC & Business Development, reported equity award activity on May 11, 2026. She converted 3,944 restricted stock units into an equal number of common shares, and 2,559 common shares were disposed of under code F to satisfy exercise price or tax obligations. She continues to hold multiple stock option, restricted stock unit and performance stock unit awards, including options on 107,450 shares at $13.05 expiring in 2035 and 147,804 shares at $10.81 expiring in 2036.
NeoGenomics Inc. President & Chief Operating Officer Warren Stone reported a routine equity compensation event. On May 11, 2026, he exercised 5,830 restricted stock units into an equal number of shares of common stock. Of these, 3,783 shares of common stock were withheld to satisfy tax obligations through a share delivery mechanism.
Following these transactions, Mr. Stone directly holds 164,032 shares of NeoGenomics common stock. The filing also lists substantial existing awards of restricted stock units, performance stock units, and stock options with various vesting schedules and premium exercise prices, reflecting a compensation package tied to service, share-price growth and revenue growth goals.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 2, 2026, he exercised 5,372 restricted stock units into common stock and, in connection with vesting, surrendered shares to the company to satisfy tax obligations. The filings show 2,246 common shares disposed through issuer withholding across May 1 and May 2, 2026, and he now directly holds 25,153 shares of common stock. He also retains multiple unexercised stock option and RSU awards with exercise prices between $9.83 and $14.62 per share and expirations extending to 2036.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported updated equity holdings in the company. The filing shows a disposition of 1,042 shares of common stock on May 1, 2026 as a tax-withholding transaction, leaving her with 92,182 common shares held directly.
Alongside these shares, she holds a range of equity awards in the form of restricted stock units, performance stock units and stock options tied to NeoGenomics common stock, with various exercise prices and expiration dates, reflecting a substantial, long-term incentive position rather than open-market trading activity.
NeoGenomics, Inc. President & Chief Operating Officer Warren Stone reported routine equity compensation activity involving restricted stock units and stock options. On May 2, 2026, he exercised awards to acquire 5,969 shares of common stock, with 2,349 shares withheld by the company to cover tax obligations related to the RSU release.
Following these transactions, Stone holds 161,985 shares of common stock directly, along with a substantial remaining equity incentive position, including 253,378 stock options at an exercise price of $10.81 and 166,113 stock options at $11.21, plus significant restricted and performance stock units that vest over future years.
NeoGenomics Inc. President & Chief Operating Officer Warren Stone reported an equity compensation event on April 1, 2026. He exercised 17,562 restricted stock units into an equal number of shares of common stock at an exercise price of $0.00 per share.
Of these shares, 6,911 were disposed of through a tax-withholding transaction to satisfy tax obligations, a non-market event. Following these transactions, Stone directly holds 158,365 shares of NeoGenomics common stock, along with multiple outstanding stock option, restricted stock unit, and performance stock unit awards as listed in the filing.
NeoGenomics Inc. Chief Executive Officer Anthony P. Zook exercised equity awards and settled related taxes using shares. On April 1, 2026, he converted 140,498 restricted stock units into the same number of common shares at a $0.00 exercise price. Of these, 45,453 common shares were withheld to cover tax obligations, leaving 133,111 common shares held directly after the transactions, plus 18,900 shares held indirectly through the Amended and Restated Anthony P. Zook Living Trust. He also continues to hold substantial stock options and restricted stock units granted in 2025 and 2026 that vest ratably over three years and have premium exercise prices based on 110% of the stock’s closing prices on the respective grant dates.
NeoGenomics Inc. Chief Accounting Officer Greg D. Aunan reported equity awards received on March 1, 2026. He was granted 36,825 stock options and 22,889 restricted stock units (RSUs), both with an exercise or acquisition price of $0.00 per share.
The stock options and RSUs each vest ratably over the first three anniversary dates of the grant date, meaning the awards vest in three equal annual installments. Once vested and settled into common shares, the shares of common stock are not subject to expiration. The filing also updates his directly owned option, RSU, and common stock balances as of the same date.
NeoGenomics Inc. executive vice president and general counsel Alicia C. Olivo reported new equity awards. On March 1, 2026, she received 147,804 stock options and 89,013 restricted stock units as compensation, both granted at an exercise/issue price of $0.00 per share.
The stock options are described as premium-price options, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest in equal installments over the first three anniversaries of the grant date, and once vested, the related common shares are not subject to expiration.
NeoGenomics Inc. reported that President & Chief Operating Officer Warren Stone received new equity awards. On March 1, 2026, he was granted 253,378 stock options and 152,594 restricted stock units, both vesting ratably over the first three anniversary dates of the grant.
The stock option grant was structured as a premium-price option, with the exercise price set at 110% of the February 27, 2026 closing share price. Footnotes also describe Mr. Stone’s existing stock options, restricted stock units, and performance stock units granted between 2022 and 2025, which vest over multi‑year and performance-based schedules.
NeoGenomics Inc. reported that Chief Executive Officer Anthony P. Zook received new equity awards. On March 1, 2026, he was granted 675,676 stock options and 406,918 restricted stock units at no cost per unit. The options are premium-price awards, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest ratably over the first three anniversaries of the grant date, tying most of the value to multi‑year service and performance. Once vested, the underlying common shares are not subject to expiration. Footnotes also reference earlier premium-price grants on April 1, 2025, indicating a continuing emphasis on performance-oriented, at-risk compensation for the CEO.
NeoGenomics President & Chief Operating Officer Warren Stone reported equity award vesting and related share-withholding transactions. On February 21 and 23, 2026, restricted stock units converted into 36,548 shares of common stock at no cash exercise price.
To cover tax obligations tied to these RSU releases, 10,465 common shares were disposed of through issuer share withholding rather than open-market sales. Following these transactions, Stone directly owned 147,714 shares of NeoGenomics common stock, along with various stock option, restricted stock unit, and performance stock unit holdings described in the filing footnotes.
NeoGenomics Chief Financial Officer Jeffrey Scott Sherman reported equity award activity, not open‑market trading. On February 21 and February 23, he converted restricted stock units into common stock in transactions coded as exercises or conversions. The filing also shows shares withheld and disposed of to cover tax obligations related to these RSU releases. After these transactions, he directly owned 220,009 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that vest over future years.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity award activity. On February 21 and 23, 2026, she converted a total of 29,522 restricted stock units into an equal number of NeoGenomics common shares at no cash exercise price. To cover tax withholding on these vestings, 11,618 common shares were disposed of through share withholding rather than open-market sales. After these transactions, she directly held 93,224 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that continue to vest over time.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported equity compensation activity. On February 21, 2026, he exercised 6,323 restricted stock units, converting them into the same number of shares of common stock at $0.00 per share, reflecting vesting of prior RSU grants. On the same date, 1,875 common shares were withheld and disposed of to cover tax obligations related to the RSU release, rather than an open-market sale. Following these transactions, he directly held 22,027 shares of common stock and maintained multiple outstanding stock option and RSU awards that vest over future anniversaries of their respective grant dates.
NeoGenomics Inc. President & Chief Operating Officer Stone Warren reported a sale of company stock. On January 20, 2026, he sold 22,128 shares of common stock at a price of $12.5037 per share, leaving him with 121,631 common shares owned directly.
The filing also lists his existing equity awards, including stock options and restricted and performance stock units granted between 2022 and 2025. These include options to buy 166,113 shares at $11.21 exercisable until December 1, 2029, and additional option grants such as 143,266 options and 94,518 options that vest in stages over two years. He also holds sizable restricted stock unit and performance stock unit awards, such as 84,317, 59,382, and 52,687 share-equivalent RSU positions, with vesting tied to continued service and, for performance units, to share price and revenue growth goals. Some options were granted at a premium exercise price set at 110% of the stock’s closing price on specified grant dates.
NeoGenomics (NEO) President & Chief Operating Officer Warren Stone reported equity activity on January 13, 2026. He acquired 59,382 shares of common stock through the vesting of restricted stock units at an effective price of $0 per share, then disposed of 15,127 shares in a transaction tied to tax withholding obligations. Following these transactions, he directly beneficially owned 143,759 shares of NeoGenomics common stock.
The filing also lists substantial outstanding equity awards, including stock options, restricted stock units, and performance stock units covering multiple future vesting and expiration dates, reflecting a significant portion of his compensation in equity incentives.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity transactions tied to previously granted awards. On January 13, 2026, 59,382 shares of common stock were acquired at $0 per share under transaction code M, reflecting the release of vested restricted stock units. In connection with this vesting, 15,145 shares were disposed of under transaction code F at $0 to cover tax withholding obligations.
Following these transactions, Ms. Olivo directly owned 75,320 shares of NeoGenomics common stock. She also held a range of equity awards, including stock options with various exercise prices and expiration dates, as well as restricted stock units and performance stock units that convert into common stock upon vesting.
NeoGenomics (NEO) executive Alicia C. Olivo (EVP, GC & Business Development) reported an open-market sale of common stock. On 10/16/2025, she sold 4,918 shares at $10.00 per share under a Rule 10b5-1 trading plan. Following this transaction, she beneficially owns 43,022 common shares directly.
Her equity awards include multiple grants shown in the filing, such as stock options with exercise prices ranging from $9.45 to $48.99, and time- and performance-based stock units, including 107,450 options with a $13.05 exercise price and 63,238 restricted stock units. The filing notes standard vesting schedules and that once vested, shares of common stock are not subject to expiration.